Investors are excited about the biotech's clinical trial results.
Compare ACRS Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: Aclaris Therapeutics
A mid-stage trial failure has investors questioning the company's approach.
ACRS earnings call for the period ending March 31, 2019.
ACRS earnings call for the period ending December 31, 2018.
ACRS earnings call for the period ending December 31, 2017.
Analyst price targets for these two biotechs suggest they could double your money. Here's what you need to know.
The pharma's shares dipped on a $65 million capital raise.
2015 was not a particularly strong year for IPOs, but these five did quite well.